ABSTRACT
Bleeding in patients with acute myeloid leukemia (AML) receiving intensive induction chemotherapy is multifactorial and contributes to early death. We sought to define incidence and risk factors of grade 4 bleeding to support strategies for risk mitigation. Bleeding events were assessed according to the WHO bleeding assessment scale, which includes grade 4 bleeding as fatal, life-threatening, retinal with visual impairment, or involving the central nervous system. Using multivariable competing-risk regression analysis with grade 4 bleeding as the primary outcome, we identified risk factors in the development cohort (n=341), which were tested in an independent cohort (n=143). Grade 4 bleeding occurred in 5.9% and 9.8% of patients in the development and validation cohort, respectively. Risk factors that were independently associated with grade 4 bleeding included baseline platelet count ≤40 ×109/L compared with >40 ×109/L, and baseline PT-INR >1.5 or >1.3-1.5 compared with ≤1.3. These variables were allocated points, which allowed for stratification of patients with low- and high-risk for grade 4 bleeding. Cumulative incidence of grade 4 bleeding at day+60 was significantly higher among patients with high- versus low-risk (development: 31±7% vs. 2±1%, P<0.001, validation: 25±9% vs. 7±2%, P=0.008). In both cohorts, high bleeding risk was associated with disseminated intravascular coagulation (DIC) and proliferative disease. We developed and validated a simple risk model for grade 4 bleeding, which enables development of rational risk mitigation strategies to improve early mortality of intensive induction treatment.
KEY POINTS
Risk factors predicting grade 4 bleeding were consistent with DIC-like coagulopathy, including prolonged PT-INR and thrombocytopenia.
The grade 4 bleeding score was externally validated and allows for preventive strategies to improve early mortality in high-risk patients.
Competing Interest Statement
R.C.L. has received research funding from Jazz Pharmaceuticals and MedImmune and consulting fees from Takeda Pharmaceuticals and bluebird bio.
Funding Statement
This work was supported by grants from the National Institutes of Health K08CA204734 (R.C.L.), the Edward P. Evans Foundation, Rubicon fellowship from the Netherlands Organization for Scientific Research (J.V), Erasmus Medical Center Foundation-Daniel den Hoed (J.V.), and Rene Vogels stipend (J.V.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Dana-Farber Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Presented in abstract form at the 62nd Annual Meeting of the American Society of Hematology, 5–8 December 2020.
Data Availability
De-identified data are available upon request.